nodes	percent_of_prediction	percent_of_DWPC	metapath
Montelukast—CYP2A6—Prednisolone—multiple sclerosis	0.144	0.247	CbGbCtD
Montelukast—CYP2A6—Dexamethasone—multiple sclerosis	0.0846	0.146	CbGbCtD
Montelukast—CYP3A4—Fingolimod—multiple sclerosis	0.0694	0.119	CbGbCtD
Montelukast—CYP3A4—Methylprednisolone—multiple sclerosis	0.0448	0.0769	CbGbCtD
Montelukast—CYP2C8—Dexamethasone—multiple sclerosis	0.0417	0.0718	CbGbCtD
Montelukast—CYP3A4—Triamcinolone—multiple sclerosis	0.0339	0.0583	CbGbCtD
Montelukast—CYP3A4—Mitoxantrone—multiple sclerosis	0.0326	0.0561	CbGbCtD
Montelukast—CYP2C9—Dexamethasone—multiple sclerosis	0.0291	0.05	CbGbCtD
Montelukast—CYP3A4—Betamethasone—multiple sclerosis	0.0291	0.05	CbGbCtD
Montelukast—CYP3A4—Prednisolone—multiple sclerosis	0.0287	0.0494	CbGbCtD
Montelukast—CYP3A4—Prednisone—multiple sclerosis	0.0271	0.0466	CbGbCtD
Montelukast—CYP3A4—Dexamethasone—multiple sclerosis	0.0169	0.0291	CbGbCtD
Montelukast—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000554	0.00769	CbGpPWpGaD
Montelukast—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000554	0.00769	CbGpPWpGaD
Montelukast—CYP2C8—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000552	0.00766	CbGpPWpGaD
Montelukast—CYP2C8—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000552	0.00766	CbGpPWpGaD
Montelukast—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000547	0.00759	CbGpPWpGaD
Montelukast—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000547	0.00759	CbGpPWpGaD
Montelukast—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.00051	0.00707	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—GPR65—multiple sclerosis	0.000483	0.0067	CbGpPWpGaD
Montelukast—Vomiting—Cladribine—multiple sclerosis	0.00047	0.00136	CcSEcCtD
Montelukast—Rash—Cladribine—multiple sclerosis	0.000466	0.00135	CcSEcCtD
Montelukast—Hallucination—Dexamethasone—multiple sclerosis	0.000466	0.00135	CcSEcCtD
Montelukast—Hallucination—Betamethasone—multiple sclerosis	0.000466	0.00135	CcSEcCtD
Montelukast—Dermatitis—Cladribine—multiple sclerosis	0.000466	0.00134	CcSEcCtD
Montelukast—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000465	0.00134	CcSEcCtD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.000464	0.00644	CbGpPWpGaD
Montelukast—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000464	0.00134	CcSEcCtD
Montelukast—Headache—Cladribine—multiple sclerosis	0.000463	0.00134	CcSEcCtD
Montelukast—PTGS1—Biological oxidations—CYP27B1—multiple sclerosis	0.000454	0.0063	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—CYP24A1—multiple sclerosis	0.000454	0.0063	CbGpPWpGaD
Montelukast—Mental disorder—Methylprednisolone—multiple sclerosis	0.000451	0.0013	CcSEcCtD
Montelukast—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000449	0.00624	CbGpPWpGaD
Montelukast—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000449	0.00624	CbGpPWpGaD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.000449	0.00622	CbGpPWpGaD
Montelukast—Angioedema—Prednisolone—multiple sclerosis	0.000446	0.00129	CcSEcCtD
Montelukast—Neuropathy peripheral—Prednisone—multiple sclerosis	0.000445	0.00129	CcSEcCtD
Montelukast—Toxic epidermal necrolysis—Methotrexate—multiple sclerosis	0.000444	0.00128	CcSEcCtD
Montelukast—Hypersensitivity—Azathioprine—multiple sclerosis	0.000443	0.00128	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000443	0.00128	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—CCR1—multiple sclerosis	0.000442	0.00613	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—CXCL13—multiple sclerosis	0.000442	0.00613	CbGpPWpGaD
Montelukast—ALOX5—Selenium Micronutrient Network—ICAM1—multiple sclerosis	0.00044	0.00611	CbGpPWpGaD
Montelukast—Nausea—Cladribine—multiple sclerosis	0.000439	0.00127	CcSEcCtD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.000436	0.00605	CbGpPWpGaD
Montelukast—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000436	0.00126	CcSEcCtD
Montelukast—Somnolence—Mitoxantrone—multiple sclerosis	0.000432	0.00125	CcSEcCtD
Montelukast—CYP2A6—Biological oxidations—CYP27B1—multiple sclerosis	0.000429	0.00596	CbGpPWpGaD
Montelukast—CYP2A6—Biological oxidations—CYP24A1—multiple sclerosis	0.000429	0.00596	CbGpPWpGaD
Montelukast—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000428	0.00123	CcSEcCtD
Montelukast—Asthma—Methotrexate—multiple sclerosis	0.000426	0.00123	CcSEcCtD
Montelukast—Convulsion—Prednisolone—multiple sclerosis	0.000423	0.00122	CcSEcCtD
Montelukast—Eosinophilia—Methotrexate—multiple sclerosis	0.000421	0.00122	CcSEcCtD
Montelukast—Fatigue—Mitoxantrone—multiple sclerosis	0.000419	0.00121	CcSEcCtD
Montelukast—Pancreatitis—Methotrexate—multiple sclerosis	0.000417	0.00121	CcSEcCtD
Montelukast—Pain—Mitoxantrone—multiple sclerosis	0.000415	0.0012	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.000413	0.00574	CbGpPWpGaD
Montelukast—Diarrhoea—Azathioprine—multiple sclerosis	0.000411	0.00119	CcSEcCtD
Montelukast—Angioedema—Triamcinolone—multiple sclerosis	0.00041	0.00119	CcSEcCtD
Montelukast—Angioedema—Methylprednisolone—multiple sclerosis	0.000409	0.00118	CcSEcCtD
Montelukast—Hallucination—Prednisone—multiple sclerosis	0.000406	0.00117	CcSEcCtD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.000403	0.00559	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000402	0.00558	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000402	0.00558	CbGpPWpGaD
Montelukast—Connective tissue disorder—Prednisone—multiple sclerosis	0.000401	0.00116	CcSEcCtD
Montelukast—Oedema—Prednisolone—multiple sclerosis	0.000399	0.00115	CcSEcCtD
Montelukast—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000399	0.00115	CcSEcCtD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000398	0.00553	CbGpPWpGaD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.000398	0.00552	CbGpPWpGaD
Montelukast—Dizziness—Azathioprine—multiple sclerosis	0.000397	0.00115	CcSEcCtD
Montelukast—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000397	0.00115	CcSEcCtD
Montelukast—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000396	0.00114	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—CCL2—multiple sclerosis	0.000394	0.00547	CbGpPWpGaD
Montelukast—Cough—Triamcinolone—multiple sclerosis	0.000392	0.00113	CcSEcCtD
Montelukast—Convulsion—Triamcinolone—multiple sclerosis	0.000389	0.00112	CcSEcCtD
Montelukast—Convulsion—Methylprednisolone—multiple sclerosis	0.000388	0.00112	CcSEcCtD
Montelukast—Urticaria—Mitoxantrone—multiple sclerosis	0.000386	0.00111	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000384	0.00533	CbGpPWpGaD
Montelukast—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000384	0.00111	CcSEcCtD
Montelukast—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000384	0.00111	CcSEcCtD
Montelukast—CYSLTR1—Endothelins—MAPK1—multiple sclerosis	0.000384	0.00533	CbGpPWpGaD
Montelukast—Myalgia—Triamcinolone—multiple sclerosis	0.000382	0.0011	CcSEcCtD
Montelukast—Vomiting—Azathioprine—multiple sclerosis	0.000382	0.0011	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000382	0.0053	CbGpPWpGaD
Montelukast—Pneumonia—Methotrexate—multiple sclerosis	0.000382	0.0011	CcSEcCtD
Montelukast—Arthralgia—Methylprednisolone—multiple sclerosis	0.000382	0.0011	CcSEcCtD
Montelukast—Myalgia—Methylprednisolone—multiple sclerosis	0.000382	0.0011	CcSEcCtD
Montelukast—Anxiety—Methylprednisolone—multiple sclerosis	0.00038	0.0011	CcSEcCtD
Montelukast—Infestation—Methotrexate—multiple sclerosis	0.00038	0.0011	CcSEcCtD
Montelukast—Infestation NOS—Methotrexate—multiple sclerosis	0.00038	0.0011	CcSEcCtD
Montelukast—Drowsiness—Methotrexate—multiple sclerosis	0.00038	0.0011	CcSEcCtD
Montelukast—Rash—Azathioprine—multiple sclerosis	0.000379	0.00109	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000379	0.00109	CcSEcCtD
Montelukast—Dermatitis—Azathioprine—multiple sclerosis	0.000379	0.00109	CcSEcCtD
Montelukast—Headache—Azathioprine—multiple sclerosis	0.000377	0.00109	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000376	0.00109	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000374	0.00519	CbGpPWpGaD
Montelukast—Angioedema—Dexamethasone—multiple sclerosis	0.000372	0.00108	CcSEcCtD
Montelukast—Angioedema—Betamethasone—multiple sclerosis	0.000372	0.00108	CcSEcCtD
Montelukast—Conjunctivitis—Methotrexate—multiple sclerosis	0.000369	0.00107	CcSEcCtD
Montelukast—Immune system disorder—Prednisone—multiple sclerosis	0.000368	0.00106	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—ALB—multiple sclerosis	0.000367	0.00509	CbGpPWpGaD
Montelukast—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000367	0.00106	CcSEcCtD
Montelukast—Oedema—Triamcinolone—multiple sclerosis	0.000367	0.00106	CcSEcCtD
Montelukast—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000366	0.00106	CcSEcCtD
Montelukast—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000366	0.00507	CbGpPWpGaD
Montelukast—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000366	0.00507	CbGpPWpGaD
Montelukast—Infection—Triamcinolone—multiple sclerosis	0.000364	0.00105	CcSEcCtD
Montelukast—Infection—Methylprednisolone—multiple sclerosis	0.000363	0.00105	CcSEcCtD
Montelukast—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000361	0.00501	CbGpPWpGaD
Montelukast—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000361	0.00501	CbGpPWpGaD
Montelukast—Insomnia—Prednisolone—multiple sclerosis	0.000361	0.00104	CcSEcCtD
Montelukast—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000359	0.00104	CcSEcCtD
Montelukast—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000359	0.00104	CcSEcCtD
Montelukast—Epistaxis—Methotrexate—multiple sclerosis	0.000358	0.00103	CcSEcCtD
Montelukast—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000358	0.00103	CcSEcCtD
Montelukast—Paraesthesia—Prednisolone—multiple sclerosis	0.000358	0.00103	CcSEcCtD
Montelukast—Mental disorder—Prednisone—multiple sclerosis	0.000357	0.00103	CcSEcCtD
Montelukast—Nausea—Azathioprine—multiple sclerosis	0.000357	0.00103	CcSEcCtD
Montelukast—Skin disorder—Methylprednisolone—multiple sclerosis	0.000355	0.00103	CcSEcCtD
Montelukast—Convulsion—Dexamethasone—multiple sclerosis	0.000353	0.00102	CcSEcCtD
Montelukast—Convulsion—Betamethasone—multiple sclerosis	0.000353	0.00102	CcSEcCtD
Montelukast—Asthenia—Mitoxantrone—multiple sclerosis	0.000349	0.00101	CcSEcCtD
Montelukast—Myalgia—Dexamethasone—multiple sclerosis	0.000347	0.001	CcSEcCtD
Montelukast—Myalgia—Betamethasone—multiple sclerosis	0.000347	0.001	CcSEcCtD
Montelukast—Anxiety—Dexamethasone—multiple sclerosis	0.000346	0.000998	CcSEcCtD
Montelukast—Anxiety—Betamethasone—multiple sclerosis	0.000346	0.000998	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000345	0.00479	CbGpPWpGaD
Montelukast—Pain—Prednisolone—multiple sclerosis	0.000341	0.000984	CcSEcCtD
Montelukast—Hepatitis—Methotrexate—multiple sclerosis	0.000341	0.000984	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000339	0.0047	CbGpPWpGaD
Montelukast—Pharyngitis—Methotrexate—multiple sclerosis	0.000338	0.000977	CcSEcCtD
Montelukast—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000336	0.000972	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—IFNG—multiple sclerosis	0.000335	0.00465	CbGpPWpGaD
Montelukast—Urethral disorder—Methotrexate—multiple sclerosis	0.000334	0.000964	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000334	0.000964	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000333	0.000962	CcSEcCtD
Montelukast—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000333	0.00096	CcSEcCtD
Montelukast—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000333	0.00096	CcSEcCtD
Montelukast—Oedema—Betamethasone—multiple sclerosis	0.000333	0.00096	CcSEcCtD
Montelukast—Oedema—Dexamethasone—multiple sclerosis	0.000333	0.00096	CcSEcCtD
Montelukast—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000332	0.00096	CcSEcCtD
Montelukast—Insomnia—Triamcinolone—multiple sclerosis	0.000332	0.000957	CcSEcCtD
Montelukast—Insomnia—Methylprednisolone—multiple sclerosis	0.000331	0.000955	CcSEcCtD
Montelukast—Infection—Dexamethasone—multiple sclerosis	0.00033	0.000954	CcSEcCtD
Montelukast—Infection—Betamethasone—multiple sclerosis	0.00033	0.000954	CcSEcCtD
Montelukast—Paraesthesia—Triamcinolone—multiple sclerosis	0.000329	0.00095	CcSEcCtD
Montelukast—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000328	0.000948	CcSEcCtD
Montelukast—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000328	0.00455	CbGpPWpGaD
Montelukast—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000326	0.000942	CcSEcCtD
Montelukast—Nervous system disorder—Betamethasone—multiple sclerosis	0.000326	0.000942	CcSEcCtD
Montelukast—Agitation—Prednisone—multiple sclerosis	0.000326	0.000942	CcSEcCtD
Montelukast—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000326	0.00094	CcSEcCtD
Montelukast—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000326	0.00094	CcSEcCtD
Montelukast—Angioedema—Prednisone—multiple sclerosis	0.000324	0.000936	CcSEcCtD
Montelukast—Dyspepsia—Triamcinolone—multiple sclerosis	0.000323	0.000932	CcSEcCtD
Montelukast—Erythema multiforme—Methotrexate—multiple sclerosis	0.000322	0.00093	CcSEcCtD
Montelukast—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000322	0.00093	CcSEcCtD
Montelukast—PTGS1—Overview of nanoparticle effects—TNF—multiple sclerosis	0.00032	0.00445	CbGpPWpGaD
Montelukast—Urticaria—Prednisolone—multiple sclerosis	0.000317	0.000914	CcSEcCtD
Montelukast—Cardiac disorder—Methotrexate—multiple sclerosis	0.000316	0.000913	CcSEcCtD
Montelukast—Fatigue—Triamcinolone—multiple sclerosis	0.000316	0.000913	CcSEcCtD
Montelukast—Fatigue—Methylprednisolone—multiple sclerosis	0.000315	0.000911	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—CCL3—multiple sclerosis	0.000315	0.00437	CbGpPWpGaD
Montelukast—Pain—Triamcinolone—multiple sclerosis	0.000313	0.000905	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000311	0.00431	CbGpPWpGaD
Montelukast—Vomiting—Mitoxantrone—multiple sclerosis	0.000309	0.000892	CcSEcCtD
Montelukast—Immune system disorder—Methotrexate—multiple sclerosis	0.000308	0.000889	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—S1PR1—multiple sclerosis	0.000308	0.00427	CbGpPWpGaD
Montelukast—Convulsion—Prednisone—multiple sclerosis	0.000307	0.000888	CcSEcCtD
Montelukast—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000307	0.000887	CcSEcCtD
Montelukast—Rash—Mitoxantrone—multiple sclerosis	0.000306	0.000885	CcSEcCtD
Montelukast—Dermatitis—Mitoxantrone—multiple sclerosis	0.000306	0.000884	CcSEcCtD
Montelukast—Headache—Mitoxantrone—multiple sclerosis	0.000304	0.000879	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000303	0.000875	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000303	0.000875	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—PTGER4—multiple sclerosis	0.000303	0.0042	CbGpPWpGaD
Montelukast—Arthralgia—Prednisone—multiple sclerosis	0.000302	0.000873	CcSEcCtD
Montelukast—Myalgia—Prednisone—multiple sclerosis	0.000302	0.000873	CcSEcCtD
Montelukast—Anxiety—Prednisone—multiple sclerosis	0.000301	0.000869	CcSEcCtD
Montelukast—Insomnia—Dexamethasone—multiple sclerosis	0.000301	0.000869	CcSEcCtD
Montelukast—Insomnia—Betamethasone—multiple sclerosis	0.000301	0.000869	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.0003	0.000866	CcSEcCtD
Montelukast—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000299	0.000864	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—IL1B—multiple sclerosis	0.000299	0.00415	CbGpPWpGaD
Montelukast—Paraesthesia—Dexamethasone—multiple sclerosis	0.000299	0.000862	CcSEcCtD
Montelukast—Paraesthesia—Betamethasone—multiple sclerosis	0.000299	0.000862	CcSEcCtD
Montelukast—Mental disorder—Methotrexate—multiple sclerosis	0.000299	0.000862	CcSEcCtD
Montelukast—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000296	0.00411	CbGpPWpGaD
Montelukast—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000296	0.00411	CbGpPWpGaD
Montelukast—Hypersensitivity—Prednisolone—multiple sclerosis	0.000294	0.000848	CcSEcCtD
Montelukast—CYP2C8—Biological oxidations—CYP27B1—multiple sclerosis	0.000293	0.00407	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—CYP24A1—multiple sclerosis	0.000293	0.00407	CbGpPWpGaD
Montelukast—Dyspepsia—Dexamethasone—multiple sclerosis	0.000293	0.000845	CcSEcCtD
Montelukast—Dyspepsia—Betamethasone—multiple sclerosis	0.000293	0.000845	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—CXCR3—multiple sclerosis	0.000293	0.00406	CbGpPWpGaD
Montelukast—Urticaria—Triamcinolone—multiple sclerosis	0.000291	0.000841	CcSEcCtD
Montelukast—Urticaria—Methylprednisolone—multiple sclerosis	0.000291	0.000839	CcSEcCtD
Montelukast—Body temperature increased—Triamcinolone—multiple sclerosis	0.00029	0.000837	CcSEcCtD
Montelukast—Anaphylactic shock—Prednisone—multiple sclerosis	0.00029	0.000836	CcSEcCtD
Montelukast—Oedema—Prednisone—multiple sclerosis	0.00029	0.000836	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.00029	0.00402	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000289	0.00401	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000289	0.00401	CbGpPWpGaD
Montelukast—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000289	0.000835	CcSEcCtD
Montelukast—Nausea—Mitoxantrone—multiple sclerosis	0.000289	0.000833	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—RGS1—multiple sclerosis	0.000288	0.004	CbGpPWpGaD
Montelukast—Infection—Prednisone—multiple sclerosis	0.000288	0.000831	CcSEcCtD
Montelukast—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000287	0.000829	CcSEcCtD
Montelukast—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000287	0.000829	CcSEcCtD
Montelukast—Fatigue—Dexamethasone—multiple sclerosis	0.000287	0.000828	CcSEcCtD
Montelukast—Fatigue—Betamethasone—multiple sclerosis	0.000287	0.000828	CcSEcCtD
Montelukast—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000286	0.00396	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—CCR2—multiple sclerosis	0.000285	0.00395	CbGpPWpGaD
Montelukast—Pain—Betamethasone—multiple sclerosis	0.000284	0.000821	CcSEcCtD
Montelukast—Pain—Dexamethasone—multiple sclerosis	0.000284	0.000821	CcSEcCtD
Montelukast—Nervous system disorder—Prednisone—multiple sclerosis	0.000284	0.00082	CcSEcCtD
Montelukast—Skin disorder—Prednisone—multiple sclerosis	0.000281	0.000812	CcSEcCtD
Montelukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000281	0.0039	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—GPR65—multiple sclerosis	0.000273	0.00379	CbGpPWpGaD
Montelukast—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000272	0.000785	CcSEcCtD
Montelukast—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000272	0.000785	CcSEcCtD
Montelukast—Hypersensitivity—Triamcinolone—multiple sclerosis	0.00027	0.00078	CcSEcCtD
Montelukast—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000269	0.000778	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000267	0.00371	CbGpPWpGaD
Montelukast—Urticaria—Betamethasone—multiple sclerosis	0.000264	0.000763	CcSEcCtD
Montelukast—Urticaria—Dexamethasone—multiple sclerosis	0.000264	0.000763	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000264	0.000762	CcSEcCtD
Montelukast—Dizziness—Prednisolone—multiple sclerosis	0.000264	0.000761	CcSEcCtD
Montelukast—Asthenia—Triamcinolone—multiple sclerosis	0.000263	0.000759	CcSEcCtD
Montelukast—Body temperature increased—Betamethasone—multiple sclerosis	0.000263	0.000759	CcSEcCtD
Montelukast—Abdominal pain—Dexamethasone—multiple sclerosis	0.000263	0.000759	CcSEcCtD
Montelukast—Abdominal pain—Betamethasone—multiple sclerosis	0.000263	0.000759	CcSEcCtD
Montelukast—Body temperature increased—Dexamethasone—multiple sclerosis	0.000263	0.000759	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—CNR1—multiple sclerosis	0.000263	0.00365	CbGpPWpGaD
Montelukast—Asthenia—Methylprednisolone—multiple sclerosis	0.000262	0.000758	CcSEcCtD
Montelukast—Insomnia—Prednisone—multiple sclerosis	0.000262	0.000756	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—RGS1—multiple sclerosis	0.000261	0.00363	CbGpPWpGaD
Montelukast—Paraesthesia—Prednisone—multiple sclerosis	0.00026	0.000751	CcSEcCtD
Montelukast—Pruritus—Triamcinolone—multiple sclerosis	0.000259	0.000749	CcSEcCtD
Montelukast—Cough—Methotrexate—multiple sclerosis	0.000259	0.000747	CcSEcCtD
Montelukast—Pruritus—Methylprednisolone—multiple sclerosis	0.000259	0.000747	CcSEcCtD
Montelukast—PTGS1—Overview of nanoparticle effects—IL6—multiple sclerosis	0.000259	0.00359	CbGpPWpGaD
Montelukast—Convulsion—Methotrexate—multiple sclerosis	0.000257	0.000742	CcSEcCtD
Montelukast—Dyspepsia—Prednisone—multiple sclerosis	0.000255	0.000736	CcSEcCtD
Montelukast—ALOX5—Metabolism—SRM—multiple sclerosis	0.000254	0.00353	CbGpPWpGaD
Montelukast—Arthralgia—Methotrexate—multiple sclerosis	0.000253	0.000729	CcSEcCtD
Montelukast—Myalgia—Methotrexate—multiple sclerosis	0.000253	0.000729	CcSEcCtD
Montelukast—Rash—Prednisolone—multiple sclerosis	0.000251	0.000726	CcSEcCtD
Montelukast—Dermatitis—Prednisolone—multiple sclerosis	0.000251	0.000725	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000251	0.000724	CcSEcCtD
Montelukast—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00025	0.000723	CcSEcCtD
Montelukast—Fatigue—Prednisone—multiple sclerosis	0.00025	0.000721	CcSEcCtD
Montelukast—Headache—Prednisolone—multiple sclerosis	0.00025	0.000721	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.00025	0.00346	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CCR1—multiple sclerosis	0.00025	0.00346	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—GPR65—multiple sclerosis	0.000248	0.00344	CbGpPWpGaD
Montelukast—Dizziness—Triamcinolone—multiple sclerosis	0.000242	0.0007	CcSEcCtD
Montelukast—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000242	0.000699	CcSEcCtD
Montelukast—Dizziness—Methylprednisolone—multiple sclerosis	0.000242	0.000698	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000241	0.00334	CbGpPWpGaD
Montelukast—Infection—Methotrexate—multiple sclerosis	0.00024	0.000694	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—LINGO1—multiple sclerosis	0.00024	0.00333	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000239	0.00331	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000239	0.00331	CbGpPWpGaD
Montelukast—Asthenia—Betamethasone—multiple sclerosis	0.000239	0.000689	CcSEcCtD
Montelukast—Asthenia—Dexamethasone—multiple sclerosis	0.000239	0.000689	CcSEcCtD
Montelukast—Nervous system disorder—Methotrexate—multiple sclerosis	0.000237	0.000686	CcSEcCtD
Montelukast—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000237	0.000684	CcSEcCtD
Montelukast—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000237	0.000684	CcSEcCtD
Montelukast—Nausea—Prednisolone—multiple sclerosis	0.000237	0.000684	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—CXCL10—multiple sclerosis	0.000237	0.00328	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000235	0.00327	CbGpPWpGaD
Montelukast—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000235	0.00327	CbGpPWpGaD
Montelukast—Pruritus—Dexamethasone—multiple sclerosis	0.000235	0.00068	CcSEcCtD
Montelukast—Pruritus—Betamethasone—multiple sclerosis	0.000235	0.00068	CcSEcCtD
Montelukast—Skin disorder—Methotrexate—multiple sclerosis	0.000235	0.000679	CcSEcCtD
Montelukast—Vomiting—Triamcinolone—multiple sclerosis	0.000233	0.000673	CcSEcCtD
Montelukast—Vomiting—Methylprednisolone—multiple sclerosis	0.000233	0.000672	CcSEcCtD
Montelukast—Rash—Triamcinolone—multiple sclerosis	0.000231	0.000667	CcSEcCtD
Montelukast—Dermatitis—Triamcinolone—multiple sclerosis	0.000231	0.000667	CcSEcCtD
Montelukast—Rash—Methylprednisolone—multiple sclerosis	0.000231	0.000666	CcSEcCtD
Montelukast—Dermatitis—Methylprednisolone—multiple sclerosis	0.00023	0.000665	CcSEcCtD
Montelukast—Urticaria—Prednisone—multiple sclerosis	0.00023	0.000664	CcSEcCtD
Montelukast—Headache—Triamcinolone—multiple sclerosis	0.00023	0.000663	CcSEcCtD
Montelukast—Headache—Methylprednisolone—multiple sclerosis	0.000229	0.000662	CcSEcCtD
Montelukast—Body temperature increased—Prednisone—multiple sclerosis	0.000229	0.000661	CcSEcCtD
Montelukast—Abdominal pain—Prednisone—multiple sclerosis	0.000229	0.000661	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000229	0.00318	CbGpPWpGaD
Montelukast—Diarrhoea—Betamethasone—multiple sclerosis	0.000228	0.000657	CcSEcCtD
Montelukast—Diarrhoea—Dexamethasone—multiple sclerosis	0.000228	0.000657	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—CCR1—multiple sclerosis	0.000227	0.00315	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CXCL13—multiple sclerosis	0.000227	0.00315	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000226	0.00313	CbGpPWpGaD
Montelukast—CYP2A6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000224	0.00311	CbGpPWpGaD
Montelukast—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000221	0.000637	CcSEcCtD
Montelukast—Dizziness—Dexamethasone—multiple sclerosis	0.00022	0.000635	CcSEcCtD
Montelukast—Dizziness—Betamethasone—multiple sclerosis	0.00022	0.000635	CcSEcCtD
Montelukast—Insomnia—Methotrexate—multiple sclerosis	0.000219	0.000632	CcSEcCtD
Montelukast—Nausea—Triamcinolone—multiple sclerosis	0.000218	0.000629	CcSEcCtD
Montelukast—Paraesthesia—Methotrexate—multiple sclerosis	0.000217	0.000628	CcSEcCtD
Montelukast—Nausea—Methylprednisolone—multiple sclerosis	0.000217	0.000627	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—TNF—multiple sclerosis	0.000217	0.00301	CbGpPWpGaD
Montelukast—Somnolence—Methotrexate—multiple sclerosis	0.000215	0.000621	CcSEcCtD
Montelukast—Hypersensitivity—Prednisone—multiple sclerosis	0.000213	0.000616	CcSEcCtD
Montelukast—Dyspepsia—Methotrexate—multiple sclerosis	0.000213	0.000615	CcSEcCtD
Montelukast—Vomiting—Dexamethasone—multiple sclerosis	0.000211	0.000611	CcSEcCtD
Montelukast—Vomiting—Betamethasone—multiple sclerosis	0.000211	0.000611	CcSEcCtD
Montelukast—Rash—Dexamethasone—multiple sclerosis	0.00021	0.000606	CcSEcCtD
Montelukast—Rash—Betamethasone—multiple sclerosis	0.00021	0.000606	CcSEcCtD
Montelukast—Dermatitis—Betamethasone—multiple sclerosis	0.00021	0.000605	CcSEcCtD
Montelukast—Dermatitis—Dexamethasone—multiple sclerosis	0.00021	0.000605	CcSEcCtD
Montelukast—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000209	0.000603	CcSEcCtD
Montelukast—Fatigue—Methotrexate—multiple sclerosis	0.000209	0.000603	CcSEcCtD
Montelukast—Headache—Dexamethasone—multiple sclerosis	0.000208	0.000602	CcSEcCtD
Montelukast—Headache—Betamethasone—multiple sclerosis	0.000208	0.000602	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—TAGAP—multiple sclerosis	0.000208	0.00288	CbGpPWpGaD
Montelukast—Asthenia—Prednisone—multiple sclerosis	0.000208	0.0006	CcSEcCtD
Montelukast—Pain—Methotrexate—multiple sclerosis	0.000207	0.000598	CcSEcCtD
Montelukast—Pruritus—Prednisone—multiple sclerosis	0.000205	0.000592	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—CCL5—multiple sclerosis	0.000204	0.00283	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000202	0.00281	CbGpPWpGaD
Montelukast—Diarrhoea—Prednisone—multiple sclerosis	0.000198	0.000572	CcSEcCtD
Montelukast—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000198	0.000572	CcSEcCtD
Montelukast—Nausea—Betamethasone—multiple sclerosis	0.000198	0.00057	CcSEcCtD
Montelukast—Nausea—Dexamethasone—multiple sclerosis	0.000198	0.00057	CcSEcCtD
Montelukast—Urticaria—Methotrexate—multiple sclerosis	0.000192	0.000555	CcSEcCtD
Montelukast—PTGS1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000192	0.00267	CbGpPWpGaD
Montelukast—Dizziness—Prednisone—multiple sclerosis	0.000192	0.000553	CcSEcCtD
Montelukast—Body temperature increased—Methotrexate—multiple sclerosis	0.000191	0.000553	CcSEcCtD
Montelukast—Abdominal pain—Methotrexate—multiple sclerosis	0.000191	0.000553	CcSEcCtD
Montelukast—PTGS1—Selenium Micronutrient Network—ICAM1—multiple sclerosis	0.000191	0.00265	CbGpPWpGaD
Montelukast—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000188	0.00261	CbGpPWpGaD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000188	0.00261	CbGpPWpGaD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000184	0.00256	CbGpPWpGaD
Montelukast—Vomiting—Prednisone—multiple sclerosis	0.000184	0.000532	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—CCR5—multiple sclerosis	0.000183	0.00255	CbGpPWpGaD
Montelukast—Rash—Prednisone—multiple sclerosis	0.000183	0.000527	CcSEcCtD
Montelukast—Dermatitis—Prednisone—multiple sclerosis	0.000182	0.000527	CcSEcCtD
Montelukast—CYP2A6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000182	0.00252	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—S1PR1—multiple sclerosis	0.000182	0.00252	CbGpPWpGaD
Montelukast—Headache—Prednisone—multiple sclerosis	0.000181	0.000524	CcSEcCtD
Montelukast—ALOX5—Metabolism—CYP24A1—multiple sclerosis	0.000179	0.00249	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—CYP27B1—multiple sclerosis	0.000179	0.00249	CbGpPWpGaD
Montelukast—Hypersensitivity—Methotrexate—multiple sclerosis	0.000178	0.000515	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—GPC5—multiple sclerosis	0.000177	0.00245	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000175	0.00243	CbGpPWpGaD
Montelukast—ALOX5—Selenium Micronutrient Network—IL6—multiple sclerosis	0.000175	0.00243	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000174	0.00242	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000174	0.00242	CbGpPWpGaD
Montelukast—Asthenia—Methotrexate—multiple sclerosis	0.000174	0.000502	CcSEcCtD
Montelukast—Nausea—Prednisone—multiple sclerosis	0.000172	0.000497	CcSEcCtD
Montelukast—Pruritus—Methotrexate—multiple sclerosis	0.000171	0.000495	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000171	0.00238	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—CCL2—multiple sclerosis	0.000171	0.00237	CbGpPWpGaD
Montelukast—Diarrhoea—Methotrexate—multiple sclerosis	0.000166	0.000478	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000165	0.00229	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—GPC5—multiple sclerosis	0.000164	0.00227	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CCL3—multiple sclerosis	0.000162	0.00224	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CCR2—multiple sclerosis	0.000161	0.00223	CbGpPWpGaD
Montelukast—Dizziness—Methotrexate—multiple sclerosis	0.00016	0.000462	CcSEcCtD
Montelukast—PTGS1—Selenium Micronutrient Network—ALB—multiple sclerosis	0.000159	0.00221	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000157	0.00218	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000157	0.00218	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—PTGER4—multiple sclerosis	0.000155	0.00216	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000155	0.00215	CbGpPWpGaD
Montelukast—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000155	0.00215	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—RGS1—multiple sclerosis	0.000154	0.00214	CbGpPWpGaD
Montelukast—Vomiting—Methotrexate—multiple sclerosis	0.000154	0.000444	CcSEcCtD
Montelukast—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000153	0.00213	CbGpPWpGaD
Montelukast—Rash—Methotrexate—multiple sclerosis	0.000153	0.000441	CcSEcCtD
Montelukast—Dermatitis—Methotrexate—multiple sclerosis	0.000152	0.00044	CcSEcCtD
Montelukast—Headache—Methotrexate—multiple sclerosis	0.000152	0.000438	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—CXCR3—multiple sclerosis	0.00015	0.00208	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CNR1—multiple sclerosis	0.000148	0.00206	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—GPR65—multiple sclerosis	0.000146	0.00203	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CCR2—multiple sclerosis	0.000146	0.00203	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—IFNG—multiple sclerosis	0.000145	0.00202	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000144	0.002	CbGpPWpGaD
Montelukast—Nausea—Methotrexate—multiple sclerosis	0.000144	0.000415	CcSEcCtD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	0.000143	0.00199	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—POMC—multiple sclerosis	0.000143	0.00199	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—CCL2—multiple sclerosis	0.00014	0.00195	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—RRM1—multiple sclerosis	0.000136	0.00188	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CNR1—multiple sclerosis	0.000135	0.00187	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CXCL13—multiple sclerosis	0.000134	0.00186	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCR1—multiple sclerosis	0.000134	0.00186	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000134	0.00185	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—IL1B—multiple sclerosis	0.00013	0.0018	CbGpPWpGaD
Montelukast—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000125	0.00173	CbGpPWpGaD
Montelukast—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000124	0.00172	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CXCL10—multiple sclerosis	0.000121	0.00168	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CCL5—multiple sclerosis	0.000115	0.0016	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000113	0.00156	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000113	0.00156	CbGpPWpGaD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.00011	0.00153	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—SRM—multiple sclerosis	0.00011	0.00153	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000105	0.00146	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CCL5—multiple sclerosis	0.000104	0.00145	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—SRM—multiple sclerosis	0.000104	0.00145	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CCR5—multiple sclerosis	0.000104	0.00144	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000102	0.00142	CbGpPWpGaD
Montelukast—PTGS1—Biological oxidations—POMC—multiple sclerosis	0.000102	0.00142	CbGpPWpGaD
Montelukast—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000101	0.0014	CbGpPWpGaD
Montelukast—CYP2A6—Biological oxidations—POMC—multiple sclerosis	9.66e-05	0.00134	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCL3—multiple sclerosis	9.54e-05	0.00132	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CCR5—multiple sclerosis	9.41e-05	0.00131	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—TNF—multiple sclerosis	9.4e-05	0.0013	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—IL2RA—multiple sclerosis	9.28e-05	0.00129	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PTGER4—multiple sclerosis	9.19e-05	0.00127	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	9.17e-05	0.00127	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	9.17e-05	0.00127	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PGR—multiple sclerosis	9.05e-05	0.00126	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.05e-05	0.00126	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CXCR3—multiple sclerosis	8.87e-05	0.00123	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CD28—multiple sclerosis	8.79e-05	0.00122	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCR2—multiple sclerosis	8.63e-05	0.0012	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.25e-05	0.00114	CbGpPWpGaD
Montelukast—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.22e-05	0.00114	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—POMC—multiple sclerosis	8.1e-05	0.00112	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CNR1—multiple sclerosis	7.96e-05	0.00111	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—BCHE—multiple sclerosis	7.8e-05	0.00108	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP27B1—multiple sclerosis	7.77e-05	0.00108	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CYP24A1—multiple sclerosis	7.77e-05	0.00108	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	7.59e-05	0.00105	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—IL6—multiple sclerosis	7.59e-05	0.00105	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—POMC—multiple sclerosis	7.36e-05	0.00102	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP24A1—multiple sclerosis	7.34e-05	0.00102	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CYP27B1—multiple sclerosis	7.34e-05	0.00102	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—ALB—multiple sclerosis	7.29e-05	0.00101	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CCL2—multiple sclerosis	7.2e-05	0.000999	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CXCL10—multiple sclerosis	7.17e-05	0.000995	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—SRM—multiple sclerosis	7.12e-05	0.000988	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—GPC5—multiple sclerosis	7.1e-05	0.000986	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—GPC5—multiple sclerosis	6.72e-05	0.000932	CbGpPWpGaD
Montelukast—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.67e-05	0.000925	CbGpPWpGaD
Montelukast—CYP2C8—Biological oxidations—POMC—multiple sclerosis	6.6e-05	0.000916	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—TYK2—multiple sclerosis	6.54e-05	0.000907	CbGpPWpGaD
Montelukast—CYP2A6—NRF2 pathway—TGFB1—multiple sclerosis	6.35e-05	0.000881	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CD86—multiple sclerosis	6.27e-05	0.00087	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCL5—multiple sclerosis	6.17e-05	0.000857	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—IL2—multiple sclerosis	5.99e-05	0.000831	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—RRM1—multiple sclerosis	5.89e-05	0.000817	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—SRM—multiple sclerosis	5.79e-05	0.000804	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SPP1—multiple sclerosis	5.72e-05	0.000793	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—RRM1—multiple sclerosis	5.57e-05	0.000772	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCR5—multiple sclerosis	5.56e-05	0.000772	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IL2RA—multiple sclerosis	5.48e-05	0.000761	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—IL2—multiple sclerosis	5.44e-05	0.000755	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—POMC—multiple sclerosis	5.37e-05	0.000745	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—APOE—multiple sclerosis	5.06e-05	0.000702	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	5.02e-05	0.000696	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	5.02e-05	0.000696	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.9e-05	0.00068	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—APOE—multiple sclerosis	4.69e-05	0.000651	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—GPC5—multiple sclerosis	4.59e-05	0.000637	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CD80—multiple sclerosis	4.57e-05	0.000635	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.57e-05	0.000634	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—POMC—multiple sclerosis	4.35e-05	0.000603	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCL2—multiple sclerosis	4.25e-05	0.00059	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—MAPK1—multiple sclerosis	4.16e-05	0.000577	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	4.08e-05	0.000566	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	4.08e-05	0.000566	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—POMC—multiple sclerosis	4.03e-05	0.000559	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.99e-05	0.000554	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.92e-05	0.000544	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TYK2—multiple sclerosis	3.86e-05	0.000536	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—SRM—multiple sclerosis	3.82e-05	0.00053	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—RRM1—multiple sclerosis	3.8e-05	0.000528	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—GPC5—multiple sclerosis	3.73e-05	0.000518	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—ALB—multiple sclerosis	3.67e-05	0.00051	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.58e-05	0.000496	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—POMC—multiple sclerosis	3.54e-05	0.000491	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—BCHE—multiple sclerosis	3.38e-05	0.000469	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IL2—multiple sclerosis	3.21e-05	0.000446	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—IL6—multiple sclerosis	3.2e-05	0.000444	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—BCHE—multiple sclerosis	3.2e-05	0.000444	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—RRM1—multiple sclerosis	3.09e-05	0.000429	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—MMP9—multiple sclerosis	3.04e-05	0.000422	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.95e-05	0.000409	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—STAT3—multiple sclerosis	2.7e-05	0.000375	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.69e-05	0.000374	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.69e-05	0.000374	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.53e-05	0.000352	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—MYC—multiple sclerosis	2.51e-05	0.000349	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TGFB1—multiple sclerosis	2.51e-05	0.000348	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.46e-05	0.000342	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—MAPK1—multiple sclerosis	2.46e-05	0.000341	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.4e-05	0.000333	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.31e-05	0.000321	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—BCHE—multiple sclerosis	2.18e-05	0.000303	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.06e-05	0.000286	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.04e-05	0.000283	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—APOE—multiple sclerosis	2.03e-05	0.000282	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—APOE—multiple sclerosis	1.92e-05	0.000267	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—IL6—multiple sclerosis	1.89e-05	0.000262	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.88e-05	0.000261	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.78e-05	0.000247	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—POMC—multiple sclerosis	1.75e-05	0.000242	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—POMC—multiple sclerosis	1.65e-05	0.000229	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—ALB—multiple sclerosis	1.59e-05	0.000221	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—ALB—multiple sclerosis	1.51e-05	0.000209	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—APOE—multiple sclerosis	1.31e-05	0.000182	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.17e-05	0.000163	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—POMC—multiple sclerosis	1.13e-05	0.000157	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—APOE—multiple sclerosis	1.07e-05	0.000148	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—ALB—multiple sclerosis	1.03e-05	0.000143	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—POMC—multiple sclerosis	9.18e-06	0.000127	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—ALB—multiple sclerosis	8.37e-06	0.000116	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—APOE—multiple sclerosis	7.05e-06	9.78e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—POMC—multiple sclerosis	6.06e-06	8.4e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—ALB—multiple sclerosis	5.52e-06	7.66e-05	CbGpPWpGaD
